Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.
|Slideshows|December 13, 2018
5 Classic Hallucinogens Studied in the Treatment of Addictions
Author(s)Michael P. Bogenschutz, MD
This slideshow provides information about the compounds, clinically relevant attributes, approximate dose, and data under study.
Advertisement
Advertisement
Related to this article
FDA grants Breakthrough Device status to NET Recovery’s tACS wearable, aiming to curb cocaine and meth use and close a major treatment gap.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
2
Muscarinic Treatment for Schizophrenia: A Presynaptic Answer to a Presynaptic Problem
3
How a Learning Health Network Could Transform Bipolar Disorder Treatment: A Conversation With Andrew Nierenberg, MD
4
First Patient Dosed in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder and Sleep Disturbance
5